Harbor Capital Advisors Inc. Boosts Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Harbor Capital Advisors Inc. grew its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 4.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,043,676 shares of the company's stock after purchasing an additional 42,288 shares during the quarter. Harbor Capital Advisors Inc. owned approximately 0.71% of MiMedx Group worth $7,932,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Invesco Ltd. lifted its position in shares of MiMedx Group by 2.2% during the 4th quarter. Invesco Ltd. now owns 56,565 shares of the company's stock valued at $544,000 after buying an additional 1,226 shares during the last quarter. Rhumbline Advisers raised its stake in MiMedx Group by 1.4% in the 1st quarter. Rhumbline Advisers now owns 177,156 shares of the company's stock valued at $1,346,000 after acquiring an additional 2,436 shares during the period. Tower Research Capital LLC TRC raised its stake in MiMedx Group by 77.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after acquiring an additional 2,837 shares during the period. IMG Wealth Management Inc. purchased a new stake in MiMedx Group during the fourth quarter valued at about $28,000. Finally, Bank of New York Mellon Corp boosted its position in MiMedx Group by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company's stock worth $4,849,000 after purchasing an additional 3,300 shares during the period. 79.15% of the stock is currently owned by institutional investors.

Insider Activity at MiMedx Group

In other news, CEO Joseph H. Capper acquired 200,000 shares of MiMedx Group stock in a transaction on Friday, May 2nd. The shares were acquired at an average price of $6.34 per share, with a total value of $1,268,000.00. Following the purchase, the chief executive officer now directly owns 529,530 shares in the company, valued at $3,357,220.20. The trade was a 60.69% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.70% of the stock is currently owned by insiders.

MiMedx Group Trading Down 1.3%

MiMedx Group stock traded down $0.08 during mid-day trading on Friday, hitting $6.04. The company's stock had a trading volume of 939,695 shares, compared to its average volume of 687,138. The stock has a market cap of $892.12 million, a price-to-earnings ratio of 10.98 and a beta of 1.82. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14. The business has a 50 day moving average price of $6.74 and a 200-day moving average price of $7.95. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. The business had revenue of $88.21 million during the quarter, compared to analysts' expectations of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. As a group, analysts forecast that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on MDXG shares. Wall Street Zen upgraded MiMedx Group from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.